Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia
Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Monday
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy